CytoReason
Agent21Agent Readiness: 21/100. Bottom 25%. Measured by StartupHub.ai. Median 41.Trust72Data Trust: 72/100. Above median. Measured by StartupHub.ai. Median 61.Develops a computational model of the human body for drug discovery and development.
About
CytoReason builds comprehensive computational disease models to map disease and drug mechanisms. Their platform enables pharmaceutical and biotech companies to manage drug portfolios, prioritize programs, and compare treatments across patient populations by integrating human data for predictable drug development. This allows scientists to gain deep drug profiles and executives to have a bird's-eye view of their entire portfolio.
Listed competitors
Also in this space
Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.
Shares Healthcare, Drug Development
AI-powered spatial biology platform for precision medicine and drug development.
Shares Healthcare, Pharmaceuticals
AI-powered IVF clinic solutions for digitization and automation.
Shares Healthcare, HealthTech
Genoox provides a cloud-based AI platform for genomic data analysis, connecting clinicians and healthcare organizations.
Shares Healthcare, Genomics
Ukko is developing novel food allergy and disorder treatments using advanced immunology and plant science.
Shares Healthcare, Genomics
Data-driven drug discovery and development company using machine learning and high-throughput biology.
Shares Healthcare, Drug Discovery
Key facts
- Website
- cytoreason.com
- Headquarters
- Tel Aviv, Israel
- Founded
- 2016
- Employees
- 116
- Total funding
- $128M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 17 Jul 2024 | Series B | $80M | Pfizer, Nvidia |
| 20 Jul 2023 | Debt | $16M | BHI (Bank Hapoalim) |
| 27 Oct 2022 | Funding Round | $4M | |
| 20 Sept 2022 | Strategic | $20M | Pfizer |
| 24 Aug 2021 | Funding Round | $8M |
Tech stack
Detected on cytoreason.com, last scanned 22 Aug 2026. Run your own scan
- Analytics
- Segment
- Email provider
- Microsoft 365
CytoReason scores 41. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is CytoReason trustworthy and reputable?
StartupHub's Data Trust & Reputation score for CytoReason is 72 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has CytoReason raised?
CytoReason has raised a total of $128M in funding. The most recent round on record is Series B.
How many employees does CytoReason have?
CytoReason has approximately 116 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for CytoReason
